From now on available at ArminLabs: The C6-ELISA

  • it is highly specific, highly immunogenic, activity associated, as well as cross-reactive with the VlsE subtypes of Borrelia burgdorferi sensu stricto, Borrelia burgdorferi garinii, and Borrelia burgdorferi afzelii.

The suitability of the C6 ELISA in the early and late stage of a Lyme Borreliosis caused by European strains of Borrelia has been proved (Liang et al. 2000).

  • a synthetic peptide is employed for the diagnosis, instead of different native and recombinant antigens in an conventional Borrelia ELISA
  • the quantitative determination of C6 in a highly specific setting represents the reaction of the patient’s immune system with the pathogen

A study by Bacon et al. revealed a increase of the sensitivity by the factor 10.
Philip et al. found a decrease of the C6 titer by the factor 4 within six months for 75% of those patients who were free of symptoms after treatment.

Consequently, the C6 Elisa can be an important diagnostic tool in addition to the Borrelia-EliSpot and the CD3-/CD57+ Cells.


  • Liang, F.T., Aberer, E. Cinco, M. et al: Antigenis Conservation of an Immunodominant Invariable Region of the VlsE Lipoprotein among European Pathogenic Genospecies of Borrelia burgdorferi s.l., J. Infect. Dis. 2000, 182: 1455-1462
  • Bacon, R.M., Biggerstaff, B.J., Schriefer, M.E. et al.: Serodiagnosis of Lyme Disease by Kinetic Enzyme-Linked Immunosorbent Assay Using Recombinant VlsE1 or Peptide Antigens of Borrelia burdorferi Compared with 2-Tiered TEsting Using Whole Cell Lysates. J. Infect. Dis. 2003, 187: 1187-1199
  • Philipp, M.T., Marques, A.R., Fawcett, P.T. et al.: C6-Test as an indicator of Therapy Outcome for Patients with Localied or Disseminated Lyme Borreliosis. J. Clin. Microbiol. 2003: 4955-4960
Borrelia Antibody Testing C6-ELISA Newsletter Download